AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00630643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04362332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: cluster randomized
Study NCT04362332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: cluster randomized
Study NCT01754376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Intravenous therapy given every 8 hours for up to 14 doses per week.
Study NCT01754376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Tablets given twice daily.
Study NCT00458445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD465
Study NCT00458445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a material that may look similar to SPD465, however, contains no active drug.
Study NCT00418067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Zotarolimus-eluting stent
Study NCT00418067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: Sirolimus-eluting stent
Study NCT00418067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte
Description: Paclitaxel-eluting stent
Study NCT00051831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Will be administered as one 200-mg capsule orally daily
Study NCT00051831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
Study NCT00051831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Will be administered as one 100-mg capsule orally twice daily
Study NCT00051831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: Will be administered as five hard gel capsules orally twice daily
Study NCT00051831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Will be administered as one 300-mg tablet orally daily
Study NCT04397640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonovue
Description: Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
Study NCT03127306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Polish version of BPS
Description: Validation of Polish Version of BPS.
Study NCT04311944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early fast-track care
Description: Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
Study NCT04311944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (deferred fast-track) care
Description: Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
Study NCT03237299 — intervention group
Intervention type: OTHER
Intervention: Collection of data
Description: Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
Study NCT03237299 — intervention group
Intervention type: OTHER
Intervention: No collection of data
Description: The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
Study NCT02985398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403 (Eptinezumab)
Study NCT02324231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 39.0°C temperature limit defining fever
Description: Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
Study NCT02324231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 38.5°C temperature limit defining fever
Description: Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
Study NCT01247844 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Shang Ring
Description: The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
Study NCT03705871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Differential Expansion
Description: Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
Study NCT03705871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fan-Fype Expander
Description: Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
Study NCT01835535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIVUS
Study NCT05458037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speed of tenaculum application
Description: Fast or slow closure of the tenaculum for application to the uterine cervix
Study NCT02994290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
Study NCT01461980 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086 + MCV4 + Tdap
Description: At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
Study NCT01461980 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MCV4 + Tdap + saline
Description: At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
Study NCT01461980 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rLP2086 + saline
Description: At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
Study NCT02994290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Postpartum HPV Immunization Quality Improvement Program
Description: The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed.
Study NCT03911180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail with straight parallel blade
Description: Petrochanteric fixation with Heracles proximal femoral nail
Study NCT00556699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Escalating intravenous repeating dose
Study NCT00556699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: Escalating intravenous repeating dose
Study NCT03947398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLIMP balloon
Description: Using BLIMP balloon to cross lesion
Study NCT03947398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low profile balloon
Description: using low profile balloon to cross lesion
Study NCT01622660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
Study NCT01622660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
Study NCT03303417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI Scan
Description: Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
Study NCT03303417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
Study NCT03303417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: Kiwifruit
Study NCT03303417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: calorie-matched sugar drink
Description: calorie-matched sugar drink
Study NCT00071539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-38
Description: Recombinant chimeric protein
Study NCT00071539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP38
Description: recombinant chimeric protein
Study NCT00818220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed umbilical cord clamping
Description: at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
Study NCT00818220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: The umbilical cord is cut within 10 seconds after birth
Study NCT04197258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social.
Study NCT01370239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3S193
Description: Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.
Study NCT02024529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion
Study NCT02024529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study NCT00723398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza 4gm oral
Description: Dietary supplement; Take 4 mg oral capsules daily
Study NCT00723398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 Mg Oral Tablet
Description: 60 mg orally every day for two years
Study NCT00723398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 30 Mg Oral Tablet
Description: 30 mg orally daily for two years
Study NCT00723398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza 4gm & Raloxifene 30mg
Description: Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
Study NCT02503709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK Inhibitor AT7519
Description: Given IV
Study NCT02503709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02503709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT02503709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Participants received TEZ/IVA orally once daily in the morning.
Study NCT00191906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Study NCT03460990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
Study NCT04067154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ALPE
Description: Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
Study NCT03098693 — intervention group
Intervention type: BEHAVIORAL
Intervention: HIV Self-Testing
Description: Access to home-based HIV self-testing kits for stable couples.
Study NCT03098693 — intervention group
Intervention type: BEHAVIORAL
Intervention: Immediate Access to ART for HIV infected couple members
Description: Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
Study NCT00191906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo, every day (QD), by mouth (PO)
Study NCT03098693 — intervention group
Intervention type: BEHAVIORAL
Intervention: Access to PrEP for HIV uninfected couple members
Description: Access to PrEP for HIV uninfected couple members.
Study NCT03368248 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
Study NCT01604915 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Caudal block
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
Study NCT01604915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
Study NCT03533101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
Study NCT03533101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
Study NCT02112344 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study NCT00333801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational Rehabilitation Program (VRP)
Description: Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
Study NCT00333801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
Study NCT00122109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 sessions Anger Management Therapy.
Description: Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
Study NCT00122109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 sessions Anger Management Therapy.
Description: Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
Study NCT02781584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: Administered orally once daily
Study NCT04219787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long BPL LRYGB
Description: LRYGB with an 180 cm BPL and an AL of 80 cm.
Study NCT02781584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FENO
Description: Administered orally once daily
Study NCT02781584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS
Description: Administered orally two times daily
Study NCT00557843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
Study NCT04219787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short BPL LRYGB
Description: The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.